ALLO
ALLO
Positions held
Your positionsALLO isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-14 · Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company
2026-09-11 · Allogene Therapeutics (ALLO) Down 11.1% Since Last Earnings Report: Can It Rebound?
2026-09-02 · Allogene Therapeutics CFO Geoffrey Parker to Retire
2026-09-02 · Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
2026-09-02 · Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
2026-08-31 · Allogene Therapeutics Announces Participation in September Investor Conference
2026-08-19 · Allogene (ALLO) Q2 2026 Earnings Call Transcript
2026-08-17 · Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
2026-08-13 · Allogene Therapeutics' Q2 Earnings Beat Estimates on Lower R&D Costs
2026-08-13 · Allogene Therapeutics Remains Attractive Given Valuation, Clinical Strategy, RBC Says
2026-08-13 · Allogene Therapeutics, Inc. Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns